Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

NCT00494442 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasm

Interventions

DRUG: KU-0059436 (AZD2281)(PARP inhibitor)
DRUG: KU-0059436 (AZD2281)(PARP inhibitor)

Sponsor

AstraZeneca

Collaborators

[object Object]